Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-11-23
2002-10-15
Huff, Sheela (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S053000, C514S054000, C514S061000
Reexamination Certificate
active
06465434
ABSTRACT:
TECHNICAL FIELD
The present invention is generally directed toward the inhibition of cancer metastasis mediated by endothelial adhesion molecules, and more specifically, toward such inhibition through the use of saccharides, glycoconjugates, antibodies, enzyme inhibitors, and other agents which disrupt such binding of cancer cells to endothelia.
BACKGROUND OF THE INVENTION
Despite enormous investments of financial and human resources, cancer remains one of the major causes of death. Current cancer therapies cure only about fifty percent of the patients who develop a malignant tumor. In most human malignancies, metastasis is the major cause of death.
Metastasis is the formation of a secondary tumor colony at a distant site. It is a multistep process of which tumor invasion is an early event. Tumor cells locally invade host tissue barriers, such as the epithelial basement membrane, to reach the interstitial stroma, where they gain access to blood vessels (“hematogenous metastasis”) or lymphatic channels for further dissemination. After invading the endothelial layer of a vessel wall, the circulating tumor cells are dislodged into the circulation and arrest in the precapillary venules of the target organ by adherence to endothelial cell lumenal surfaces, or exposed basement membranes. The tumor cells again invade the vascular wall to enter the organ parenchyma. Finally, the extravasated tumor cell grows in a tissue different from where it originated.
Most cancer cells fail to survive in the circulation and it appears that normally the lining of blood vessels acts as a barrier to tumor cell extravasation. Endothelial injury or perturbation increases tumor metastasis. In addition, certain factors, such as cytokines, have been shown to substantially increase the adhesion of cancer cells to treated endothelium in vitro. Interleukin 1 (IL-1) and tumor necrosis factor (TNF), which are cytokines, each stimulate the biosynthesis and expression of a cell surface receptor called ELAM-1 (endothelial leukocyte adhesion molecule). ELAM-1 is a member of a family of calcium-dependent cell adhesion receptors, known as LEC-CAMs or selecting, which includes LECAM-1 and GMP-140 (also known as PADGEM or CD62). During an inflammatory response, ELAM-1 on endothelial cells functions as a “homing receptor” for leukocytes. Recently, ELAM-1 on endothelial cells was shown to mediate the increased adhesion of colon cancer cells to endothelium treated with cytokines (Rice and Bevilacqua,
Science
246:1303-1306, 1989).
In most human malignancies, distant metastases are often too small to be detected at the time the primary tumor is treated. Furthermore, widespread initiation of metastatic colonies usually occurs before clinical symptoms of metastatic disease are evident. The size and age variation in metastases, their dispersed anatomical location, and their heterogeneous composition are all factors that hinder surgical removal and limit the concentration of anticancer drugs that can be delivered to the metastatic colonies. It has been estimated, for example, that in 1991 there will be over 60,000 deaths and over 150,000 new cases from just colorectal cancer in the U.S. alone.
Due to the difficulties in the current approaches to the treatment and prevention of metastases, there is a need in the art for improved methods and compositions for inhibiting metastasis mediated by endothelial adhesion molecules. The present invention fills this need, and further provides other related advantages.
SUMMARY OF THE INVENTION
Briefly stated, the present invention provides methods and compositions for the inhibition of cancer metastasis mediated by endothelial adhesion molecules. In one aspect, the present invention provides methods for inhibiting, within a biological preparation, the binding of malignant cells expressing sialyl Le
a
or di-sialyl Le
a
, to endothelial cells. In one embodiment, the method comprises incubating the biological preparation with at least one agent that inhibits the binding of malignant cells expressing sialyl Le
a
or di-sialyl Le
a
, to endothelial cells expressing a LEC-CAM. In another embodiment, the method comprises incubating the biological preparation with at least one agent that inhibits the binding of malignant cells expressing sialyl Le
a
or di-sialyl Le
a
, to endothelial cells expressing ELAM-1. In another embodiment, the method comprises incubating the malignant cells with at least one enzyme inhibitor that inhibits the biosynthesis of sialyl Le
a
or di-sialyl Le
a
by the malignant cells.
In another aspect of the present invention, methods are provided for inhibiting the spread of malignant cells expressing sialyl Le
a
or di-sialyl Le
a
, to secondary sites in a warm-blooded animal. In one embodiment, the method comprises administering to a warm-blooded animal an effective amount of at least one agent that inhibits the binding of malignant cells expressing sialyl Le
a
or di-sialyl Le
a
, to endothelial cells expressing a LEC-CAM. In another embodiment involving hematogenous metastasis, the method comprises administering to a warm-blooded animal an effective amount of at least one agent that inhibits the binding of malignant cells expressing sialyl Le
a
or di-sialyl Le
a
, to endothelial cells expressing ELAM-1. In another embodiment, the method comprises administering to a warm-blooded animal an effective amount of at least one enzyme inhibitor that inhibits the biosynthesis of sialyl Le
a
or di-sialyl Le
a
by the malignant cells.
In a related aspect, methods are provided for inhibiting within a biological preparation the binding of malignant cells expressing sialyl Le
a
, di-sialyl Le
a
or sialyl Le
x
, to endothelial cells. In one embodiment, the method comprises incubating a biological preparation, containing endothelial cells expressing a LEC-CAM, with at least one agent capable of reacting with both sialyl Le
a
and sialyl Le
x
. In another embodiment, the method comprises incubating a biological preparation, containing endothelial cells expressing ELAM-1, with at least one agent capable of reacting with both sialyl Le
a
and sialyl Le
x
.
In another related aspect, methods are provided for inhibiting the spread of malignant cells expressing sialyl Le
a
, di-sialyl Le
a
or dialyl Le
x
, to secondary sites in a warm-blooded aminal. In one embodiment, the method comprises administering to a warm-blooded animal an effective amount of at least one agent capable of reacting with both sialyl Le
a
and sialyl Le
x
. In another embodiment involving hematogenous metastasis, the method comprises administering to a warm-blooded animal an effective amount of at least one agent capable of reacting with both sialyl Le
a
and sialyl Le
x
.
REFERENCES:
patent: 4471057 (1984-09-01), Koprowski et al.
patent: 4851511 (1989-07-01), Hakomori et al.
patent: 4859769 (1989-08-01), Karlsson et al.
patent: 4876199 (1989-10-01), Hakomori
patent: 4946830 (1990-08-01), Pulverer et al.
patent: 5143712 (1992-09-01), Brandley et al.
patent: 5211937 (1993-05-01), Brandley et al.
patent: 5723583 (1998-03-01), Seed et al.
patent: 381 310 (1990-08-01), None
patent: 408 859 (1991-01-01), None
patent: WO 90/13300 (1990-11-01), None
patent: WO 91/19502 (1991-12-01), None
patent: WO 92/01718 (1992-02-01), None
patent: WO 92/07572 (1992-05-01), None
Baeckström et al., “Purification and Characterization of a Membrane-bound and a Secreted Mucin-type Glycoprotein Carrying the Carcinoma-associated Sialyl-LeaEpitope on Distinct Core Proteins,”J. Biol. Chem. 266(32):21537-21547, 1991.
Berg et al., “A Carbohydrate Domain Common to Both Sialyl Leaand Sialyl LexIs Recognized by the Endothelial Cell Leukocyte Adhesion Molecule ELAM-1,”J. Biol. Chem. 266(23):14869-14872, 1991.
Berg et al., “The Cutaneous Lymphocyte Antigen Is a Skin Lymphocyte Homing Receptor for the Vascular Lectin Endothelial Cell-Leukocyte Adhesion Molecule 1,”J. Exp. Med. 174:1461-1466, 1991.
Bird and Kimber, “Oligosaccharides Containing Fucose Linked &agr;(1-3) and &agr;(1-4) to N-Acetylglucosamine Cause Decompaction of Mouse Morulae,”Devel. B
Berg Ellen L.
Butcher Eugene C.
Magnani John L.
Huff Sheela
SEED Intellectual Property Law Group PLLC
Stanford University
LandOfFree
Methods and compositions for the inhibition of cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the inhibition of cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the inhibition of cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2925635